

The Scientific Journal of Medical Scholar



Publisher: Real-Publishers Limited (Realpub LLC)

30 N Gould St Ste R, Sheridan, WY 82801, USA

Co-Publisher: SSES, Egypt

Website: <https://realpublishers.us/index.php/sjms/index>

The Scientific Journal of
Medical Scholar

Available online at Journal Website
<https://realpublishers.us/index.php/sjms/index>
Subject (Audiology)



Original Article

Therapeutic Role of Vitamin B12 in Patients with Chronic Tinnitus: A pilot Study.

Israa Taha H. Ibrahim*
Noha Mohamed Elsayed
Abeer Abdellatif E. Mousa

Mostafa Adly Tantawy
Sahar Abdellatif Elsayw

Shimaa Abdelazim A. Metwally
Nadia Lotfy Hussieny

Mona Taha A. Hegazy
Amal Mohamed Elsaid

Rawan Hamdoun El-Hosiny Mohammed

Department of Ear, Nose and Throat Diseases, Audiovestibular Unit, Al Ahrar Teaching Hospital, Zagazig, Egypt.

Article information

Submitted: April 10th, 2023

Revised: June 13th, 2023

Accepted: June 13th, 2023

DOI: 10.55675/sjms.v2i3.48

Citation: Ibrahim ITH, Tantawy MA, Metwally SAA, Hegazy MTA, Elsayed NM, Elsayw SA, Husseiny NL, Elsaid AM, Mousa AAE, Mohammed RHE. Therapeutic Role of Vitamin B12 in Patients with Chronic Tinnitus: A pilot Study. SJMS 2023; 2 (3): 96-102. DOI: 10.55675/sjms.v2i3.48

ABSTRACT

Background and Aim: True tinnitus had no audible acoustic origin and is a phantom auditoria experience originating from a cause or trigger in the cochlea, brainstem, or at highly centers. The Jastreboff neurophysiologic hypothesis, which emphasizes that tinnitus is a subcortical sensation and originates from the interpretation of weak neuronal activities in the peripherals, is the most widely recognized. This research seeks to understand the function of vitamin B12 in the management of chronic tinnitus.

Methods: A total of 100 individuals participated in this randomized, double-blinded pilot study, of whom 50 in Group A (patients) obtained intramuscular treatment of 1 ml Vitamin B12 (2500 mcg) once a week for a duration of six weeks, while the remaining 50 subjects in Group B (controls) obtained isotonic saline as a placebo. Pre- and post-treatment audiological and a Vitamin B12 testing were performed on the subjects.

Results: When standard dosages of vitamin B12 were set at 250 pg/ml, 43% of the overall tinnitus patients showed deficiencies. Upon receiving Vitamin B12 medication, individuals in Group A with Vitamin B12 insufficiency significantly improved their average tinnitus intensity index value and visual analogue scale (VAS), according to a paired t-test.

Conclusions: This study shows the substantial predominance of Vitamin B12 deficiency among-and the improved performance in tinnitus severity results and VAS in cobalamin-deficiency patients receiving intramuscular Vitamin B12 once a week for six weeks. It also establishes a connection between cobalamin deficiency and tinnitus, suggesting that B12 may be used therapeutically in cobalamins-deficient tinnitus subjects.

Keywords: Vitamin B12; Tinnitus Matching; Tinnitus; Audiometry; Neuropathy.



This is an open-access article registered under the Creative Commons, ShareAlike 4.0 International license (CC BY-SA 4.0) (<https://creativecommons.org/licenses/by-sa/4.0/legalcode>).

* Corresponding author

Email: tahaisraa580@gmail.com

INTRODUCTION

Since the dawn of civilization, tinnitus has presented as a problem for people, as documented in Egyptian papyri (6000 BC) ⁽¹⁾.

The symptoms of tinnitus include ringing, roaring, or buzzing in the ears. These are all classified as tinnitus since they all come from the head in some manner ⁽²⁾.

Tinnitus may occasionally be caused by a supply of acoustic energy in the head and neck region, such as vascular abnormalities, myoclonic seizures, clicking jaws, pulmonary or cochlear otoacoustic emissions, etc., which may be detected by a second person regardless of the use of specific gear ⁽³⁾. True tinnitus, on the other hand, is a phantom auditory impression with no audible acoustic source and originates from an origin or triggers in the cochlea, brainstem, or at higher centres. Tinnitus can be categorized as main or secondary ⁽³⁾. Tinnitus that is idiopathic and can either be or not be connected to sensorineural deafness is known as main tinnitus ⁽⁴⁾.

Tinnitus with a recognized organic ailment or a specified causative agent (besides sensorineural deafness) is known as secondary tinnitus. It is a sign of numerous auditory and non-auditory system issues, including such simple cerumen impactions of the external auditory canals, middle ears conditions like otosclerosis or Eustachian tubes dysfunctions, cochlear malformations like Meniere's disorder, and auditory nerves pathology like vestibular schwannoma ⁽⁵⁾.

The Jastreboff neurophysiological hypothesis, which emphasizes that tinnitus is a subcortical experience and originates from the interpretation of weaker neuronal activities in the peripheral, is the most widely accepted, even though the precise reason of tinnitus remains unknown ⁽⁶⁾. Tinnitus-related neuronal behaviours, which typically occurs close to the system's edge, is processed in subcortical auditory pathways before being recognized as sounds at a level of conscious awareness ⁽⁷⁾. Similar to any neural activities produced by the external noises by the cochlea, the volume and frequency of tinnitus rely on the amplitude and patterns of electrical impulses coming at the temporal lobes' cortexes after subcortical signals recognition and feature matching have performed ⁽⁸⁾.

Due in large part to the fact that the source of tinnitus remains unknown, there has not yet been an effective therapy for the condition. Although the auditory system and nearby anatomical locations have been implicated in tinnitus creation, no tests can now accurately pinpoint these areas ⁽⁹⁾. There is currently universal agreement that tinnitus is caused by abnormal neuronal activities, typically of an excitatory character, in the auditory system ⁽¹⁰⁾. There

have been many new medications that claim to help in tinnitus management. The vitamin B12 deficiency in tinnitus sufferers was discovered by Shemesh et al. in 1993, and its treatment was demonstrated to help these individuals ⁽¹¹⁾.

The purpose of this investigation is to identify Vitamin B12's function in the management of tinnitus. Hypomethylations in central nervous system constitutes one of the strategies thought to be at work in vitamin B12 deficient neuropathy. An appropriate blood supply and healthy nerves tissues are required for cochlear functioning. Axonal degenerations, demyelinations, and consequent apoptotic neuronal death are all linked to B12 deficiency ⁽¹²⁾. Lack of vitamin B12 might culminate in hearing impairment by demyelinating neurons in the auditory nerve. Moreover, lower intakes of vitamin B12 and folates are linked to the breakdown of the stria vascularis' microvasculature, which could cause hearing impairment, tinnitus, and diminished endocochlear potentiality ⁽¹³⁾. The article's goal was to determine how common Vitamin B12 insufficiency is and what the treatment effects of Vitamin B12 injections on tinnitus are.

PATIENTS AND METHODS

Type of study: This was a pilot, double-blinded, randomized, placebo-controlled trial.

Study setting and duration: The study was conducted at Audio vestibular medicine unit ENT Department Al Ahrar teaching hospital from March 2022 to February 2023.

Patients: The survey included all adults aged between 18 and 60 years old with chronic subjectively tinnitus who visited the ENT outpatient clinics. Tinnitus that lasts longer than six months, occurs frequently, and is so acute that a sufferer seeks therapy at a clinic is considered to have chronic tinnitus.

Inclusion criteria: Adult subjects between the ages of 18 and 60 who have sensorineural hearing loss that has lasted longer than six months with chronic subjectively tinnitus unbiased towards gender and having average intelligence.

Exclusion criteria: Individuals with pulsatile (objective) tinnitus or participants with any heart abnormalities that could cause an otological issue would be disqualified from the research. Individuals with any infectious otological condition as well as those experiencing any form of psychological illness will be disqualified from the trial. Individuals with otological conditions other than tinnitus and sensorineural deafness or those who have experienced recent acoustic trauma or ongoing noise exposures, individuals with

systemic conditions that may cause otological issues, such as anaemia, hypertension, diabetes mellitus, and hypothyroidism and those who have used any additional medications over the last four weeks that are associated with tinnitus, such as corticosteroids, cyclendalates, and vasodilators were excluded. Individuals with ear operations, tinnitus following a head trauma, or any kind of organic disease in the neck and head area were also eliminated.

Procedures:

A whole 100 individuals participated in this randomized, double-blind pilot trial, with 50 cases in Group A (patients) and 50 participants in Group B. (controls). Twenty participants from the group A were assigned randomly, and they underwent parenteral intramuscular treatment for six weeks, receiving 1 ml of vitamin B12 (2500 mcg) each week. Identical intramuscular administration of 1 ml of placebo isotonic saline in group B (50 participants) for 6 weeks. Both the sufferer and the physician were unaware of the treatment plan. The examiners wrote down the findings. The researcher evaluated the findings.

Following a thorough history and examination, patients with chronic subjective tinnitus lasting longer than six months having undergone audiometry, tinnitus matching (pitch and noise level), a Vitamin B12 test (pre and post medications) by chemiluminescence technique, and a self-reported using a tinnitus severity index survey⁽¹⁴⁾. Following receiving interventional treatment for six weeks, the individuals were followed for a total of one month. Participants underwent tinnitus screening, Vitamin B12 assays, tinnitus severity index assessment, pure tone audiometry, and a self-reported tinnitus survey once more.

Ethical considerations:

To participate in the trial, all patients were required to complete an informed consent form. The research was carried out in line with Heliniski's declaration.

Statistical analysis:

Statistical analysis was performed using MS Microsoft Excel version 13 and SPSS version 26.0 (IBM, Chicago, IL, USA). For categorical data, percentage was determined, while means and standard deviations were determined for continuous data. The student t-test was employed to determine the value of the variance for continuous data, and the chi-square analysis was performed to determine the relationship between categorical data. $P < 0.05$ was regarded as statistically significant. The logistic regression used took into account the following variables: sex (males or females), age category (from 18 to 29, from 30 to 49 and from 50 to 60

years old), tinnitus condition (existence and normal status of tinnitus), outcome reactions of therapy (yes/no), tinnitus period, Vitamin B12 amount (low/normal), and frequencies.

RESULTS

Personal traits of the study participants

The males to female's ratio equaled 2:3, and the average age of the tinnitus subjects was 37.26 years. Since adequate amount of vitamin B12 was set at 250 pg/ml, vitamin B12 deficiency was detected in 43% of participants. Its incidence is notably high. Tinnitus symptoms lasted an average of 1.25 ± 1.2 years. 73 percent of instances of tinnitus were unilateral, with the right ear accounting for 33 percent of subjects and the left for 41 percent of total participants (Table 1).

Distribution of patients in Groups A and B

The incidence of vitamin B12 deficiency was 44.19% in patients' group and 55.81% among control individuals (Table 2).

Tinnitus severity scores of patient's pre- and post-therapy with Vitamin B₁₂ injections

The average tinnitus severity scores significantly improved in Group A patients with Vitamin B12 deficiency following Vitamin B12 medication according to a paired t-test ($t = 2.53$, $P = 0.015$, $df = 17$). Yet, neither the severity index scoring of Group A participants without B12 deficiency nor those of Group B individuals undergoing a placebo significantly improved (Table 3).

In addition, the average visual analogue score (VAS) for Group A individuals with Vitamin B12 insufficiency was 3.23 ± 0.73 before treatment and 2.78 ± 0.36 after treatment. Upon treatment, the VAS revealed a substantial reduction in tinnitus loudness ($t = 2.02$, $P = 0.03$, $df = 17$). The outcomes of Vitamin B12 medication in vitamin deficiency people are positive and encouraging, according to the studies. Some groups did not significantly progress after treatment.

Audiological assessments of tinnitus in individuals with and without a Vitamin B12 deficiency

30 participants (about 30%) in Group A and four individuals (20%) in Group B both showed subjective improvements. There was no statistically relevant difference in the two groups' perceived tinnitus improvements. Tinnitus sufferers with Vitamin B12 deficiency had an average pitch of 5.8 ± 2.2 kHz, while those with typical Vitamin B12 doses had an average pitch of 5.5 ± 2.6 kHz (kHz). Individuals with Vitamin B12 deficiency had average tinnitus loudness scores of $4.1 \pm$

2.9 (db SL) while those with adequate B12 doses had 5.0 \pm 2.8 (db SL) (Table 4).

Average hearing thresholds contrast between Groups A and B

There was no clear differentiation between the pitch and loudness scores for both groups, indicating that

vitamin B12 doses have no effect on pitch and loudness. Furthermore, it was discovered that Group A and Group B's average hearing sensitivities were nearly identical (Table 5, $P > 0.05$). All subjects' routine hemograms were completed normally. Respondents experience maximal difficulties with tinnitus in a quiet area, falling asleep, and trouble ignoring tinnitus in the tinnitus severity scale.

Table (1): Personal traits of the study participants

		Variable	n = 100
Gender		Male	40 (40%)
		Female	60 (60%)
Age (in years)	Mean \pm SD		37.26 \pm 11.39
	Age group	18-29	30 (30%)
		30-49	50 (50%)
	50-60	20 (20%)	
Vitamin B ₁₂ deficiency (n, %)		Yes	43 (43%)
		No	57 (57%)
Tinnitus duration (in years)			1.25 \pm 1.2
Tinnitus tolerance level		Unilateral	73 (73%)
		Bilateral	27 (27%)
Affected ear		Right	33 (33%)
		Left	41 (41%)
		Both ears	26 (26%)

Table (2): Distribution of patients in Groups A and B

Group	Without B ₁₂ deficiency (n=57)	With B ₁₂ deficiency (n=43)	Statistics
Group A (injection B ₁₂)	25 (43.86%)	19 (44.19%)	$\chi^2 = 0.81, P = 0.22$
Group B (injection NS)	32 (56.1%)	24 (55.81%)	

NS = Normal saline

Table (3): Tinnitus severity scores of patient's pre- and post-therapy with Vitamin B₁₂ injections

Group	Mean tinnitus severity index score		Significance t, P
	Posttherapy	Pretherapy	
Group A (injection B ₁₂)			
Without B ₁₂ deficiency	36.12 \pm 10.1	37.05 \pm 11.0	t=0.21, P=0.74
With B ₁₂ deficiency	27.29 \pm 6.3	35.49 \pm 7.5	t=2.53, P=0.015*
Group B (injection NS)			
Without B ₁₂ deficiency	33.09 \pm 7.3	32.00 \pm 7.1	t=0.27, P=0.69
With B ₁₂ deficiency	31.29 \pm 8.1	31.79 \pm 8.6	t=0.10, P=0.80

NS = Normal saline, df = Degree of freedom, *Significant as $P < 0.05$ associated with paired t-test.

Table (4): Audiological assessments of tinnitus in individuals with and without a Vitamin B12 deficiency

Tinnitus parameters	Normal Vitamin B ₁₂	Vitamin B ₁₂ deficiency	t, P and df
Tinnitus loudness (db SL)	5.0 \pm 2.8	4.1 \pm 2.9	0.94, 0.35, 37
Tinnitus pitch (kHz)	5.5 \pm 2.6	5.8 \pm 2.2	0.25, 0.60, 37

df = Degree of freedom, P-value using independent t-test.

Table (5): Average hearing thresholds contrast between Groups A and B

Group	Without B ₁₂ deficiency (db)	With B ₁₂ deficiency (db)
Group A (injection B ₁₂)	28.44 \pm 11.63	27.86 \pm 19.20
Group B (injection NS)	24.19 \pm 10.39	23.05 \pm 15.63
Significance (Group A vs. Group B)	t=1.12, P=0.15	t=0.72, P=0.15

NS = Normal saline, independent t-test was used for calculating P-value.

DISCUSSION

Tinnitus incidence in adults is regularly estimated by epidemiological research to be between 10% and 15% of the global population^(15, 16). In the Beaver Dam offspring research, which included more than 3000 adults aged 21 to 84 between 2005 and 2008, 10.6% of the participants indicated having tinnitus of at least moderate degree or difficulties maintaining sleep⁽¹⁷⁾.

Tinnitus was shown to be higher commonly found in females (70.52%) and to be bilaterally distributed (89.5%) in individuals with auditory neuropathy spectrum. In people with lower frequencies hearing impairment, the reported pitch was higher with a flat design of loss, while the subjectively pitch was lower-pitched⁽¹⁸⁾.

In the United States, the frequency of regular tinnitus rose with age, reaching a peak of 14.3% between 60 and 69 years old⁽¹⁹⁾. As people get older, tinnitus is more common⁽²⁰⁾.

Males are more likely than females to experience tinnitus⁽²¹⁾. Nonetheless, the current analysis indicated that women were more likely to have it than men (M: F = 2:3). About 25% of tinnitus patients claim that their condition has gotten worse over time⁽¹⁵⁾.

Tinnitus is thought to affect 4.5 million people in India, despite the lack of precise statistics on the incidence of the condition. Extrapolating from the total population of 1,065,070,607, it is thought that 47,928,177 Indians might have tinnitus. These extrapolations of incidence for tinnitus are merely estimations depending on the population of India and the incidence ratios from the US (or a comparable nation)⁽²²⁾.

The findings from our research indicate that the population aged 18 to 60 years has a greater incidence of serum cobalamin insufficiency, with concentrations as higher as 43% when the threshold level was set at 250 pg/ml and 15% when the threshold was set at 150 pg/ml, both of which are statistically significant. Despite low serum cobalamin values, these individuals' hemograms didn't reveal anything unusual.

In 1993, **Shemesh et al.**⁽¹¹⁾ observed that tinnitus sufferers lacked sufficient Vitamin B12, and that these patients benefited from its administration. Individuals with tinnitus and noise-induced hearing problems had a 47% incidence of cobalamin insufficiency, compared to 27% of nontinnitus individuals with the same condition.

Based on the threshold used to define a cobalamin shortage in serum, the incidence of subnormal vitamin B12 levels in older people in an Indian study ranges from 3% to 40.5%⁽²³⁾.

In another study, 67% of males had lower vitamin B12 concentrations (considering 150 pmol/L as the criteria; 68% were rural, 51% lived in slums, and 81% were middle-class urban)⁽²⁴⁾. Another finding revealed that 16% of the sample individuals had maladjusted plasma concentrations of vitamin B12 (lower than 150 pmol/l)⁽²³⁾.

Once the cutoff was set at 250 pg/ml and 180 pg/ml, respectively, the incidence of cobalamins insufficiency in tinnitus sufferers in this research was extremely greater and comparable (43%) to the findings of **Shemesh et al.**⁽¹¹⁾ and at 15% comparable to **Shobha et al.**⁽²⁵⁾.

According to **Stouffer and Tyler**⁽¹⁵⁾, tinnitus is bilaterally found in 52% of instances, unilateral in 37% of patients, located in the cranium rather than the ear in 10% of instances, and thought to be emanating from outside the head in 1% of instances.

According to **Berkiten et al.**⁽²⁶⁾, 43% and 57% of the participants, respectively, experienced bilateral and single-sided tinnitus. Yet, in this investigation, tinnitus more frequently manifested unilaterally in 73% of patients (right ear in 33% and left ear in 67% of instances), and in both ears in 26% of patients. Even though Group A's healthy cobalamin values had the greatest levels of tinnitus, the cobalamin-deficient group showed a considerable increase. There was no relationship between the loudness and pitch of tinnitus and serum cobalamin contents.

Tinnitus has been linked to issues with the cochlea, auditory nerves, and peripheral auditory tract in a number of different ideas.

Hypomethylation in the central nervous system is among the processes thought to be at work in vitamin B12 deficient neuropathy. S-adenosylmethionines (SAM) shortage inhibits methylation activities in the myelin sheath as a consequence of suppression of the B12-dependent enzymatic methionine synthases, which causes a decrease in the proportion of S-adenosylmethionines (SAM) to S-adenosylhomocysteines (SAH). Both methylcobalamin, an effective component of vitamin B₁₂, and the active component of folic acid are necessary for the methylation of homocysteines into methionines (5-methyltetrahydrofolates)⁽²⁷⁾.

Lack of vitamin B12 causes homocysteines, a neurotoxic and vascular toxin, to build up in the body. An appropriate blood supply and healthy nerve tissues are required for cochlear functionality. Axonal degenerations, demyelination, and consequent apoptosis neuronal death are all linked to B12 deficiency. Homocysteine has been linked to both vascular diseases and brain atrophy as risk factors⁽²⁸⁾.

As opposed to levels below 8.6 µmol/L, Homocysteine

values exceeding 11.9 mol/L were linked to an almost 3-fold greater risk of white matter injury ⁽²⁹⁾.

A lack of vitamin B12 might result in hearing loss as well as tinnitus by demyelinating the neurons in the cochlear nerve ⁽³⁰⁾. Moreover, lower levels of vitamin B12 and folates are linked to the breakdown of the stria vascularis' microvasculature, which could cause deafness, tinnitus, and diminished endocochlear capability ⁽³⁰⁾.

For the first time, **Martvnez-Vega *et al.*** ⁽³¹⁾ showed that the link between hyperhomocysteinemia brought on by a folate deficit and early deafness includes impaired cochlear homo-cysteines metabolisms and related oxidative stress.

High incidence of *Helicobacter pylori* and dietary practices including vegetarianism, insufficient consumption of dairy products and milk, as well as socioeconomic variables, may all contribute to the elevated incidence of vitamin B12 insufficiency. Symptoms of cobalamin insufficiency include hematological and neurological problems. The authors recommend serum cobalamin measurement in individuals who have ongoing tinnitus in light of the report's results, which indicate that cobalamin insufficiency could also emerge as tinnitus solely in the lack of other indications.

Tinnitus therapeutic interventions range from various drugs like antipsychotic drugs, vasodilators, herbal products, neurotonics, and cerebral cognitions enhancing drugs to tinnitus retraining medications, psychodynamic psychotherapy treatment ⁽³¹⁾, and lower-frequency recurrent transcranial magnetic stimulation. The etiology of tinnitus is as diverse as the range of tinnitus therapeutic interventions ⁽³²⁾.

Conclusion

It is crucial to investigate the biology of tinnitus and discover treatments for this bothersome ailment in the ever-noisier environment of rapid living and bad eating practices. Given the high frequency of cobalamin insufficiency, the findings point to the importance of assessing serum Vitamin B12 amounts in individuals with chronic tinnitus. This pilot study clarifies the link between low B12 concentrations and tinnitus, and its supplementations have a therapeutic effect on the condition, albeit more research with bigger populations is needed to confirm and establish a clear connection.

Financial and non-financial relationships and activities of interest: None.

REFERENCES

1. Abdelmawgoud S. Vitamin D Level and its Relation to Tinnitus. *EJENTAS* 2021;22(22):1-5. doi: 10.21608/ejentas.2020.37810.1243
2. Luetzenberg F, Babu S, Seidman M. Alternative treatments of tinnitus: alternative medicine. *Otolaryngol Clin North Am* 2020;53(4):637-50. doi: 10.1016/j.otc.2020.03.011
3. Li L, Shi H, Wang M. A pilot randomized controlled trial of transcutaneous electrical nerve stimulation for patients with acute tinnitus. *Med* 2019; 98(1). e13793 doi: 10.1097/MD.00000000000013793.
4. Kim SH, Kim D, Lee JM, Lee SK, Kang HJ, Yeo SG. Review of Pharmacotherapy for Tinnitus. *Healthcare (Basel)*. 2021 Jun 21; 9(6):779. doi: 10.3390/healthcare9060779.
5. Kang D, Kim S, Park D, Kim S, Yeo S. Objective and measurable biomarkers in chronic subjective tinnitus. *Int J Mol Sci* 2021;22(12):6619. doi: 10.3390/ijms22126619.
6. Kisli M, Saçmacı H. Auditory Brainstem Response in Patients with Tinnitus Associated with Vitamin B12 Deficiency. *Acta Neurol Taiwan*. 2019 Sep 15;28(3):59-65. PMID: 32002975.
7. Slanina T, Petrovičová L, Massányi P. Role of natural substances and vitamin supplementation in tinnitus prevention and treatment. *J Microbiol Biotechnol Food Sci* 2021;2021:987-94. doi: 10.15414/jmbfs.2016/17.6.3.987-994.
8. Gunay M, Baklaci D, Kuzucu I. Analysis of factors affecting the success of betahistine treatment in patients with idiopathic subjective tinnitus. *B-ENT* 2020; 16 (3): 158-63. doi: 10.5152/B-ENT.2021.20151.
9. Luetzenberg FS, Babu S, Seidman MD. Alternative Treatments of Tinnitus: Alternative Medicine. *Otolaryngol Clin North Am*. 2020 Aug;53(4):637-650. doi: 10.1016/j.otc.2020.03.011.
10. AL-Kanani F, Al-joda B. Assessment of Vitamin B12, Copper and Potassium Levels in Adults Patients with Tinnitus In Hilla City? Iraq. *Syst Rev Pharm* 2021; 12 (4): 1297-300. doi: 10.31838/srp.2021.1.193.
11. Shemesh Z, Attias J, Ornan M, Shapira N, Shahar A. Vitamin B12 deficiency in patients with chronic-tinnitus and noise-induced hearing loss. *Am J Otolaryngol* 1993;14(2):94-9. doi: 10.1016/0196-0709(93)90046-A

12. Chhaya V, Patel D, Mehta S, Rajvir J, Jhunjhuwadia V, Sehgal P, et al. Current therapeutic trends for tinnitus cure and control—a scoping review. *medRxiv* 2021;2021.06. doi: 10.1101/2021.06.29.21259450
13. Petridou A, Zagora E, Petridis P, Korres G, Gazouli M, Xenelis I, et al. The effect of antioxidant supplementation in patients with tinnitus and normal hearing or hearing loss: a randomized, double-blind, placebo controlled trial. *Nutrients* 2019;11(12):3037. doi: 10.3390/nu11123037.
14. Meikle M, Griest S, Stewart B, Press L, editors. Measuring the negative impact of tinnitus: A brief severity index. *Abstr Assoc Res Otolaryngol* 1995. doi: 10.1177/1084713808319943.
15. Stouffer J, Tyler R. Characterization of tinnitus by tinnitus patients. *J Speech Hear Disord* 1990; 55(3):439-53. doi: 10.1044/jshd.5503.439.
16. Sindhusake D, Mitchell P, Newall P, Golding M, Rochtchina E, Rubin G. Prevalence and characteristics of tinnitus in older adults: the Blue Mountains Hearing Study: Prevalencia y características del acúfeno en adultos mayores: el Estudio de Audición Blue Mountains. *Int J Audiol* 2003;42(5):289-94. doi: 10.3109/14992020309078348.
17. Nondahl D, Cruickshanks K, Huang G, Klein B, Klein R, Javier Nieto F, et al. Tinnitus and its risk factors in the Beaver Dam offspring study. *Int J Audiol* 2011;50(5):313-20. doi: 10.3109/14992027.2010.551220.
18. Chandan H, Prabhu P, Deepthi M. Prevalence and characteristics of tinnitus in individuals with auditory neuropathy spectrum disorder. *Hearing Balance Commun* 2013;11(4):214-7. doi: 10.3109/21695717.2013.821755.
19. Shargorodsky J, Curhan G, Farwell W. Prevalence and characteristics of tinnitus among US adults. *Am J Med* 2010; 123:711-8. doi: 10.1016/j.amjmed.2010.02.015.
20. Ahmad N, Seidman M. Tinnitus in the older adult: epidemiology, pathophysiology and treatment options. *Drugs Aging* 2004;21:297-305. doi: 10.2165/00002512-200421050-00002.
21. Lockwood A, Salvi R, Burkard R. Tinnitus. *N Engl J Med* 2002; 347(12):904-10. doi: 10.1056/NEJMra013395.
22. Vempati A, Prakash S, Rathna S, Sandhya K. Management options for individuals with tinnitus—a review. *Int J Sci Res* 2013;2:290-4. doi: 10.15373/22778179/FEB2013/98.
23. Lindenbaum J, Rosenberg I, Wilson P, Stabler S, Allen R. Prevalence of cobalamin deficiency in the Framingham elderly population. *Am J Clin Nutr* 1994;60(1):2-11. doi: 10.1093/ajcn/60.1.2.
24. Yajnik CS, Deshpande SS, Lubree HG, Naik SS, Bhat DS, Uradey BS, Deshpande JA, Rege SS, Refsum H, Yudkin JS. Vitamin B12 deficiency and hyperhomocysteinemia in rural and urban Indians. *J Assoc Physicians India*. 2006 Oct; 54:775-82. PMID: 17214273.
25. Shobha V, Tarey SD, Singh RG, Shetty P, Unni US, Srinivasan K, Kurpad AV. Vitamin B₁₂ deficiency & levels of metabolites in an apparently normal urban south Indian elderly population. *Indian J Med Res*. 2011 Oct;134(4):432-9. PMID: 22089603.
26. Berkiten G, Yildirim G, Topaloglu I, Ugras H. Vitamin B12 levels in patients with tinnitus and effectiveness of vitamin B12 treatment on hearing threshold and tinnitus. *B-ENT*. 2013;9(2):111-6. PMID: 23909117.
27. Metz J. Pathogenesis of cobalamin neuropathy: deficiency of nervous system S-adenosyl-methionine? *Nutr Rev* 1993; 51(1):12-5. doi: 10.1111/j.1753-4887.1993.tb03046.x.
28. den Heijer T, Vermeer S, Clarke R, Oudkerk M, Koudstaal P, Hofman A, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. *Brain* 2002;126(1):170-5. doi: 10.1093/brain/awg006.
29. Wright C, Paik M, Brown T, Stabler S, Allen R, Sacco R, et al. Total homocysteine is associated with white matter hyperintensity volume: the Northern Manhattan Study. *Stroke* 2005; 36(6): 1207-11. doi: 10.1161/01.STR.0000165923.02318.22.
30. Krumholz A, Weiss H, Goldstein P, Harris K. Evoked responses in vitamin B12 deficiency. *Annals of Neurology: Ann Neurol* 1981;9(4):407-9. doi: 10.1002/ana.410090417.
31. Martínez-Vega R, Garrido F, Partearroyo T, Cediél R, Zeisel S, Martínez-Alvarez C, et al. Folic acid deficiency induces premature hearing loss through mechanisms involving cochlear oxidative stress and impairment of homocysteine metabolism. *FASEB* 2015; 29(2): 418. doi: 10.1096/fj.14-259283.
32. Piccirillo J, Garcia K, Nicklaus J, Pierce K, Burton H, Vlassenko A, et al. Low-frequency repetitive transcranial magnetic stimulation to the temporoparietal junction for tinnitus. *Arch Otolaryngol Head Neck Surg* 2011;137(3):221-8. doi: 10.1001/archoto.2011.3.

The Scientific Journal of Medical Scholar

SJMS | E-ISSN: 2833-3772 | Volume 2, Issue 3 | May-June 2023

Publisher: Real-Publishers Limited (Realpub LLC)

30 N Gould St Ste R, Sheridan, WY 82801, USA

Co-Publisher: SSES, Egypt

Website: <https://realpublishers.us/index.php/sjms/index>